Elyufor susp. oral 0.2 / 5ml 90ml vials. 1 PC

Description

Composition
Active substance:
nifuroxazide – 200.0 mg
Excipients:
sucrose – 1000.0 mg; Sodium hydroxide – 2.0 mg; methyl parahydroxybenzoate – 5.0 mg; Carbomer – 10.5 mg;
Simethicone (30% Emulsion) – 10.5 mg; citric acid monohydrate – 0.7 mg; Banana flavor – 10.0 mg; water – up to 5 ml.
Description:
The suspension of yellow color with a characteristic odor. Appearance of a precipitate is allowed, a homogeneous suspension after shaking.
Product form:
Oral suspension 200 mg / 5 ml.
90 ml of suspension into dark glass bottles or polyethylene terephthalate bottles, sealed with a lid made of polyethylene or polypropylene with a first opening control or a screw cap with tamper-evident.
Per vial label glued on the basis of self-adhesive film.
Each vial together with instructions for use, as well as with measuring spoon is placed in a cardboard box (pack).
Equipment is allowed to 2 or 3 cartons (packs) in multipacks (transportation) of paperboard for consumer packaging.
Contraindications
– increased sensitivity to nifuroxazide, nitrofuran derivatives or any of the excipients of the formulation;
– fructose intolerance;
– syndrome glucose-galactose malabsorption, or lack of sucrase and isomaltase;
– pregnancy;
– the neonatal period (up to 1 month), prematurity
Dosage
40 mg / ml
Indications
Acute bacterial diarrhea flowing without deterioration in general condition, fever, intoxication.
Interaction with other drugs
Not recommended simultaneous application of drugs causing development disulfiramopodobnyh reactions drugs depressing the central nervous system function.
If you are taking any other medications (including over the counter) before using Elyufor drug, consult your physician.
Overdose
Symptoms of overdose are not known.
treatment is symptomatic
pharmachologic effect
Pharmacological group:
antimicrobial agent
Pharmacodynamics:
Nifuroxazide – an antimicrobial agent, a derivative of nitrofuran. Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp.; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Very sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae, Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp ,, Pseudomonas spp. Presumably blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and several others. Biochemical processes in the microbial cell.
It does not violate the balance of intestinal microflora. In acute bacterial diarrhea restoring intestinal eubioz. When infected by viruses enterotropnymi prevents the development of bacterial superinfection
Pharmacokinetics:
After oral administration nifuroxazide practically not absorbed from the digestive tract, and its antibacterial effect has only in the lumen of the intestine. Nifuroxazide output intestine: 20% unchanged and the remainder nifuroxazide – chemically modified.
Pregnancy and breast-feeding
In animal studies there was no evidence of teratogenic effects. However, as a precautionary measure to take nifuroxazide during pregnancy is not recommended.
During the period of lactation is possible to continue breastfeeding in the case of a short course of treatment with the drug. It is necessary to consult with your doctor.
Conditions of supply of pharmacies
Without a prescription.
side effects
Allergic reactions (rash, urticaria, angioneurotic edema, anaphylactic shock). If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
In the treatment of diarrhea at the same time with the therapy should be carried out nifuroxazide rehydration therapy. Treatment of diarrhea in children under 3 years old should be under the supervision of a physician.
In the case of bacterial diarrhea with signs of systemic damage (deterioration of general condition, fever, symptoms of intoxication or infection) should consult a doctor to decide on the use of antimicrobials for systemic effects.
In connection with the content of methyl parahydroxybenzoate drug can cause allergic reactions (possibly delayed).
During therapy with Elyufor prohibited alcohol.
If you have symptoms of an allergic reaction (including shortness of breath, rash, pruritus) discontinue use of the drug.
The effect on the ability to operate vehicles, machinery
The drug has no effect on the ability to drive vehicles and mechanisms.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children.
Dosing and Administration
It is used inside.
Used for dispensing spoon dosing volume of 5 ml, 2.5 ml having a grading.
Before use, the suspension must be shaken well.
Babies from 1 to 6 months: 100 mg (2.5 ml) 2-3 times a day (range 8-12 hours between doses).
Children from 6 months to 3 years: 100 mg (2.5 ml) three times a day (the interval between doses 8 hours).
Children from 3 to 6 years: 200 mg (5 ml) 3 times a day (the interval between doses 8 hours).
Children 6 to 18 years: 200 mg (5 ml) 3-4 times a day (the interval between doses 6-8 hours).
Adults: 200 mg (5 mL), 4 times a day (range 6 hours between doses).
The duration of treatment 5-7 days, but no more than 7 days. If within the first 3 days of no improvement, you should consult your doctor. Use drug only according to the application and in those doses which are specified in the instruction. If necessary, please consult your physician before using the drug.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist